[1] MAO L，JIN H J，WANG M D，et al. Neurologic

manifestations of hospitalized patients with

coronavirus disease 2019 in Wuhan，China[J].

JAMA Neurol，2020，77（6）：683-690.

[2] YAGHI S，ISHIDA K，TORRES J，et al. SARS2-

CoV-2 and Stroke in a New York Healthcare

System[J]. Stroke，2020，51（7）：2002-2011.

[3] AGGARWAL G，LIPPI G，MICHAEL HENRY

B. Cerebrovascular disease is associated with

an increased disease severity in patients with

Coronavirus Disease 2019（COVID-19）：a pooled

analysis of published literature[J]. Int J Stroke，2020，

15（4）：385-389.

[4] ZHOU P，YANG X L，WANG X G，et al. A

pneumonia outbreak associated with a new

coronavirus of probable bat origin[J]. Nature，2020，

579（7798）：270-273.

[5] HOFFMANN M，KLEINE-WEBER H，

SCHROEDER S，et al. SARS-CoV-2 cell entry

depends on ACE2 and TMPRSS2 and is blocked

by a clinically proven protease inhibitor[J/OL]. Cell，

2020，181（2）：271-280. e8[2020-07-01]. https：//doi.

org/10.1016/j.cell.2020.02.052.

[6] WRAPP D，WANG N S，CORBETT K S，et al.

Cryo-EM structure of the 2019-nCoV spike in the

prefusion conformation[J]. Science，2020，367

（6483）：1260-1263.

[7] WRIGHT J W，HARDING J W. The brain reninangiotensin

system：a diversity of functions and

implications for CNS diseases[J]. Pflugers Arch，

2013，465（1）：133-151.

[8] SOUTH A M，DIZ D I，CHAPPELL M C.

COVID-19，ACE2，and the cardiovascular

consequences[J/OL]. Am J Physiol Heart Circ

Physiol，2020，318（5）：H1084-H1090[2020-07-01].

https：//doi.org/10.1152/ajpheart.00217.2020.

[9] MONTEIL V，KWON H，PRADO P，et al.

Inhibition of SARS-CoV-2 infections in engineered

human tissues using clinical-grade soluble human

ACE2[J/OL]. Cell，2020，181（4）：905-913. e7[2020-

07-01]. https：//doi.org/10.1016/j.cell.2020.04.004.

[10] GUZIK T J，MOHIDDIN S A，DIMARCO A，et

临床研究，进一步探索SARS-CoV-2引起脑血

管病及中枢神经系统的病理生理机制，同时加

强COVID-19与脑血管疾病的横断面研究和队

列研究，明确病毒感染大流行期间脑血管病的

临床特点及预后因素。

al. COVID-19 and the cardiovascular system：

implications for risk assessment，diagnosis，and

treatment options[J]. Cardiovasc Res，2020，116（10）：

1666-1687.

[11] GUO X J，THOMAS P G. New fronts emerge in the

influenza cytokine storm[J]. Semin Immunopathol，

2017，39（5）：541-550.

[12] HUANG C L，WANG Y M，LI X W，et al. Clinical

features of patients infected with 2019 novel

coronavirus in Wuhan，China[J]. Lancet，2020，395

（10223）：497-506.

[13] XU X L，HAN M F，LI T T，et al. Effective

treatment of severe COVID-19 patients with

tocilizumab[J]. Proc Natl Acad Sci U S A，2020，117

（20）：10970-10975.

[14] ESENWA C C，ELKIND M S. Inflammatory risk

factors，biomarkers and associated therapy in

ischaemic stroke[J]. Nat Rev Neurol，2016，12（10）：

594-604.

[15] SHAAFI S，SHARIFIPOUR E，RAHMANIFAR R，

et al. Interleukin-6，a reliable prognostic factor for

ischemic stroke[J]. Iran J Neurol，2014，13（2）：70-

76.

[16] BARRIOS-LÓPEZ J M，REGO-GARCÍA I，

MUÑOZ MARTÍNEZ C，et al. Ischaemic stroke

and SARS-CoV-2 infection：a causal or incidental

association?[J]. Neurologia，2020，35（5）：295-302.

[17] TANG N，LI D J，WANG X，et al. Abnormal

coagulation parameters are associated with poor

prognosis in patients with novel coronavirus

pneumonia[J]. J Thromb Haemost，2020，18（4）：

844-847.

[18] OXLEY T J，MOCCO J，MAJIDI S，et al. Largevessel

stroke as a presenting feature of COVID-19

in the young[J/OL]. N Engl J Med，2020，382

（20）：e60[2020-07-01]. https：//doi.org/10.1056/

NEJMc2009787.

[19] The Lancet Haematology. COVID-19 coagulopathy：

an evolving story[J/OL]. Lancet Haematol，2020，

7（6）：e425[2020-07-01]. https：//doi.org/10.1016/

S2352-3026（20）30151-4.

[20] COHEN J. The immunopathogenesis of sepsis[J].

Nature，2002，420（6917）：885-891.

[21] LEVI M，THACHIL J，IBA T，et al. Coagulation

abnormalities and thrombosis in patients with

COVID-19[J/OL]. Lancet Haematol，2020，7（6）：

e438-e440[2020-07-01]. https：//doi.org/10.1016/

S2352-3026（20）30145-9.

[22] TANAKA T，NARAZAKI M，KISHIMOTO T.

Immunotherapeutic implications of IL-6 blockade

for cytokine storm[J]. Immunotherapy，2016，8（8）：959-970.

[23] VARGA Z，FLAMMER AJ，STEIGER P，et

al. Endothelial cell infection and endotheliitis in

COVID-19[J]. Lancet，2020，395（10234）：1417-

1418.

[24] PONS S，FODIL S，AZOULAY E，et al. The

vascular endothelium：the cornerstone of organ

dysfunction in severe SARS-CoV-2 infection[J]. Crit

Care，2020，24（1）：353.

[25] WU Z Y，MCGOOGAN J M. Characteristics of

and important lessons from the coronavirus disease

2019（COVID-19）outbreak in China：summary of

a report of 72 314 cases from the Chinese Center for

Disease Control and Prevention[J]. JAMA，2020，323

（13）：1239-1242.

[26] AHMAD I，RATHORE F A. Neurological

manifestations and complications of COVID-19：a

literature review[J/OL]. J Clin Neurosci，2020，

77：8-12[2020-07-01]. https：//doi.org/10.1016/

j.jocn.2020.05.017.